['primary open angle glaucoma', 'ocular hypertension']
['pro-122', 'krytantek ofteno®']

        Inclusion Criteria:

          -  18 years of age or older

          -  male or female.

          -  obtained in the external consultation.

          -  With diagnosis primary of open-angle glaucoma and / or hypertension classified as
             mild, moderate or severe glaucomatous damage, users of Krytantek Ofteno® at least two
             months prior to inclusion and under control of the target IOP.

          -  informed consent.

        Exclusion Criteria:

        General Criteria

          1. Subjects with topical or systemic medication that interferes decisively in the results
             of the study. (Such as topical immunomodulators, lacrimal point tamponade,
             corticosteroids, ocular hypotensives other than those listed above, artificial tears
             with preservative).

          2. Subjects (female) with an active sex life who are not using a contraceptive method.

          3. Female Subjects in pregnancy or breastfeeding.

          4. Female subjects with positive urine pregnancy test.

          5. Positive drug addiction (verbal interrogation).

          6. Subjects who have participated in any clinical research study in the last 40 days.

          7. Legally or mentally disabled subjects to give informed consent for their participation
             in this study.

          8. Subjects who can not comply with the appointments or with all the requirements of the
             protocol.

        Ophthalmologic criteria

          1. Subject with only one eye with vision.

          2. Subjects with visual capacity 20/200 or worse.

          3. Subjects with a narrow-angle history without treatment, with or without total or
             partial closure of the angle in either eye.

          4. Subjects with corneal abnormalities that prevent applanation tonometry.

          5. Subjects with ocular surgery or ocular trauma 6 months prior to inclusion.

          6. Any ocular laser surgery 3 months prior.

          7. Any uncontrolled or progressive retinal disease.

          8. Inflammatory diseases of any kind.

          9. Contact lens wearers.

         10. Subjects with a history of hypersensitivity to any of the ingredients of the research
             product or its analogues.
      